[Phase 3 multicenter clinical study of 111In-DTPA-D-octreotide (MP-1727) in patients with gastrointestinal hormone producing tumors].
A phase 3 multicenter clinical study was performed to investigate the efficacy, safety and usefulness of MP-1727, a novel tumor imaging agent which binds to somatostatin receptors, in 23 patients with gastrointestinal hormone producing tumor. The efficacy was graded effective or very effective in 16 cases (76.2%) out of 21 cases who could be evaluated. Positive predictive accuracy was 77.8% (7/9) for carcinoids, 100% (5/5) for gastrinomas and 40.0% (2/5) for insulinomas. In three cases, tumor lesions which had been unknown were detected by MP-1727 scintigraphy. The consistent ratio between scintigraphically positive sites and preinjection localizations was 82.0% (41/50 sites) in total. Although adverse drug reactions were observed in two cases, the safety was graded 'not problematic at all' in all of 23 cases. These results show that MP-1727 is a very useful radiopharmaceutical for detection and localization of gastrointestinal hormone producing tumors.
Yamamoto
K
K
Department of Radiology, Fukui Medical School.
Ishii
Y
Y
Furudate
M
M
Ito
K
K
Tsukamoto
E
E
Kanamaru
R
R
Endo
K
K
Hirano
T
T
Tanaka
K
K
Ogino
Y
Y
D000328:Adult; D000368:Aged; D002276:Carcinoid Tumor / Q000000981:diagnostic imaging; D005260:Female; D015408:Gastrinoma / Q000000981:diagnostic imaging; D005935:Glucagonoma / Q000000981:diagnostic imaging; D006801:Humans; D007205:Indium Radioisotopes; D007340:Insulinoma / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D015282:Octreotide; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging*; D004369:Pentetic Acid; D011237:Predictive Value of Tests; D011877:Radionuclide Imaging; D012680:Sensitivity and Specificity; D013005:Somatostatinoma / Q000000981:diagnostic imaging
D007205:Indium Radioisotopes; D004369:Pentetic Acid; D015282:Octreotide